[{"indications": "Indications\u00a0see notes above and under Dose (specialist supervision in hospital)", "name": "METYRAPONE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "6 Endocrine system", "6.7 Other endocrine drugs", "6.7.3 Metyrapone"], "cautions": "Cautions\u00a0gross hypopituitarism (risk of precipitating\r\nacute adrenal failure); hypertension on\r\nlong-term administration; hypothyroidism\r\n(delayed response); many drugs\r\ninterfere with diagnostic estimation of steroids; avoid in acute porphyria (section 9.8.2)Driving\u00a0Drowsiness may affect the\r\nperformance of skilled tasks (e.g. driving)", "side-effects": "Side-effects\u00a0occasional nausea, vomiting, dizziness, headache,\r\nhypotension, sedation; rarely abdominal pain, allergic skin reactions,\r\nhypoadrenalism, hirsutism", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/4479.htm", "doses": ["Differential diagnosis of ACTH-dependent Cushing\u2019s syndrome,\r\n750\u00a0mg every 4 hours for 6 doses; child 15\u00a0mg/kg (minimum 250\u00a0mg) every 4 hours for 6 doses", "Management of Cushing\u2019s syndrome, range 0.25\u20136\u00a0g daily, tailored\r\nto cortisol production; see notes above", "Resistant oedema due to increased aldosterone secretion in cirrhosis,\r\nnephrotic syndrome, and congestive heart failure (with glucocorticoid\r\nreplacement therapy) 3\u00a0g daily in divided doses"], "pregnancy": "Pregnancy\u00a0avoid (may impair biosynthesis of fetal-placental\r\nsteroids)"}]